Alessio Alogna, one of the founders of NanoPhoria, presented our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event, which was held this year in Chicago (AHA 2022) Posted on 5 November 202210 February 2026 by Ed Gover
NanoPhoria receives a 3.5M€ seed grant from Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London and Milan Posted on 22 May 202210 February 2026 by Ed Gover
NanoPhoria has been granted an exclusive patent licence for a drug delivery platform based on inorganic nanoparticles. This acquisition will aid in the launch new products capable of optimizing the results of therapies and reducing side effects for patients Posted on 16 May 202210 February 2026 by Ed Gover
